New hope for advanced breast cancer: drug combo trial targets resistant tumors
NCT ID NCT07330544
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 18 times
Summary
This study tests whether adding the drugs entinostat and anlotinib to the standard hormone therapy fulvestrant can shrink tumors or slow cancer growth in people with advanced HR+/HER2- breast cancer that has worsened after prior treatments. About 118 women aged 18 and older will participate. The goal is to find a better treatment option for this hard-to-treat cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGZhejiang, Hangzhou, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.